Business
Ovarian cancer selected as 2nd MATINS trial cohort
Ovarian cancer selected as 2nd MATINS trial cohort.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 9328A Faron Pharmaceuticals Oy 27 January 2020 \n\nFaron Pharmaceuticals Oy\n(\"Faron\" or the \"Company\")\n \nMATINS TRIAL UPDATE \nOvarian cancer selected as second expansion cohort\n \nCompany announcement, 27 January 2020 at 9.00 AM (EET)Inside information\n \nTURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the second expansion cohort in its phase I/II MATINS clinical trial investigating the safety and efficacy of Clevegen will be in patients with ovarian cancer. \n \nThe ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours.\n \nInitiation of this second expansion cohort follows approval from the MATINS trial's data monitoring committee earlier this month to initiate the study's first expansion cohort in patients suffering from late-stage colorectal cancer (CRC). Ovarian cancer is a tumour type known to host a significant number of Clever-1 positive tumour associated macrophages (TAM). It presents a high unmet medical need with few available treatments for patients. Large transcript analysis of ovarian tumours indicates significant outcome differences between patients with either high or low Clever-1 expression. Patients with high Clever-1 expression have short life expectancies under current treatment options.\n \nDr. Markku Jalkanen, Faron's CEO, said: \"Data collected so far in the MATINS trial are highly encouraging, with Clevegen establishing itself as a potential immunotherapy capable of downregulating a range of major inhibitory immune checkpoints (PD-1, PD-L1, CTLA-4) across several cancers. Initiation of this additional expansion cohort signals our commitment to rapidly progress the development of Clevegen in patients with limited effective treatment options.\"\n \nDr. Tyler Curiel, Professor and The Daisy M. Skinner President's Chair in Cancer Immunology Research, UT Health San Antonio, and MATINS trial site investigator and principal investigator for USA, said: \"Ovarian cancer is devastating and there remains a huge need for new ...